Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

2-1-2013

Pharmacokinetic profiles for oral and subcutaneous methotrexate
in patients with Crohn's disease
A. Wilson
Western University

V. Patel
Western University

N. Chande
Western University

T. Ponich
Western University

B. Urquhart
Western University

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Wilson, A.; Patel, V.; Chande, N.; Ponich, T.; Urquhart, B.; Asher, L.; Choi, Y.; Tirona, R.; Kim, R. B.; and Gregor,
J. C., "Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease"
(2013). Paediatrics Publications. 2324.
https://ir.lib.uwo.ca/paedpub/2324

Authors
A. Wilson, V. Patel, N. Chande, T. Ponich, B. Urquhart, L. Asher, Y. Choi, R. Tirona, R. B. Kim, and J. C.
Gregor

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/2324

Alimentary Pharmacology and Therapeutics

Pharmacokinetic proﬁles for oral and subcutaneous
methotrexate in patients with Crohn’s disease
A. Wilson*, V. Patel*, N. Chande*, T. Ponich*, B. Urquhart†, L. Asher†, Y. Choi‡, R. Tirona†, R. B. Kim† & J. C. Gregor*

*Department of Medicine, Division of
Gastroenterology, University of
Western Ontario, London, ON,
Canada.
†
Department of Medicine, Division of
Clinical Pharmacology, University of
Western Ontario, London, ON,
Canada.
‡
Department of Epidemiology and
Biostatistics, University of Western
Ontario, London, ON, Canada.

Correspondence to:
Dr A. Wilson, London Health Sciences
Centre – Victoria Campus, 800
Commissioners Rd E, Rm E1-317,
London, Ontario N6A 5W9, Canada.
E-mail: awilson2008@meds.uwo.ca

Publication data
Submitted 21 March 2012
First decision 13 April 2012
Resubmitted 25 October 2012
Accepted 3 November 2012
EV Pub Online 28 November 2012

SUMMARY
Background
Methotrexate (MTX) is administered subcutaneously to Crohn’s Disease
(CD) patients. There are very few studies evaluating the use of oral (PO)
MTX in CD. A drug and its pharmaceutical alternative are equivalent (bioequivalence) when the bioavailability of the alternative falls within 80–125%
of the bioavailability of the standard (US Food and Drug Administration FDA).
Aim
To compare the pharmacokinetic (PK) proﬁles of PO and subcutaneous
(SC) MTX in CD patients to determine the bioequivalence of these two
routes.
Methods
Eleven patients received a PO and an SC MTX dose (25 mg) separated by
one week over a two-week interval. Blood samples were collected at speciﬁed times over a 24-h period for each patient on two separate days. MTX
plasma levels were obtained using sensitive mass spectrometry. Areas under
the curve (AUC) were compared between the two routes.
Results
The mean AUC values were 3375 ng/mL 9 h (PO MTX) and 3985 ng/
mL 9 h (SC MTX). The mean AUC ratio (PO/SC) was 0.86 (0.62–1.08).
This correlates with a relative PO bioavailability of 86% in comparison to
SC. The 90% conﬁdence interval for the mean AUC (PO/SC) ratio is
(0.785, 0.929). There were no adverse events.
Conclusions
The mean MTX AUC (PO/SC) in these patients falls outside the 90% conﬁdence interval for the bioequivalence limit. SC MTX is more bioavailable
than PO MTX; however, the mean relative MTX bioavailability (PO/SC)
nearly met the FDA bioequivalence standard and PO MTX could be proposed in responders who would prefer this route.
Aliment Pharmacol Ther 2013; 37: 340–345
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INTRODUCTION
Crohn’s Disease is an incurable chronic inﬂammatory
condition that can involve any part of the gastrointestinal tract. The inﬂammation of CD follows a discontinuous course along the gut’s length and may involve all its
layers, from mucosa to serosa. CD affects 400 000–
600 000 individuals in North America with an increasing
annual incidence.1 Its course is punctuated by periods of
exacerbation and remission.
Since the ﬁrst published use of methotrexate (MTX),
a dihydrofolate reductase inhibitor, in CD by Kozarek
in 1989,2 MTX has been shown to be an effective treatment for the induction and maintenance of remission
in this patient population.3, 4 However, such randomised controlled studies have only evaluated the parenteral administration of MTX; there has been ongoing
debate about the relative oral (PO) absorption of this
drug in CD patients. Smaller nonrandomised studies
have reported conﬂicting data regarding the bioavailability of PO vs. parenterally administered MTX in CD
patients.5, 6
Orally administered MTX is effective for treating
cutaneous lupus erythematosus, sarcoidosis and rheumatoid arthritis (RA).7–9 Furthermore, frequent intramuscular (IM)/subcutaneous (SC) injections have been
associated with peripheral nerve injury, local irritation,
pain, bleeding, ﬁbrosis, abscess, gangrene and contractures.10 There may also be increased costs and inconvenience for the patient with this mode of drug
administration. Patients typically prefer oral therapy
over parenteral therapy. Therefore, the PO administration of MTX may be preferred for patients with CD
over injections if proven to be bioequivalent. Currently,
there are no recommendations regarding the PO
administration of MTX in CD.
Bioavailability refers to the rate and extent to which a
drug is absorbed and becomes available in the systemic
circulation. Bioequivalence refers to the equivalent
release of the same drug substance from two or more
drug formulations as well as the equivalent rate and
extent of absorption from these formulations. According
to the US Food and Drug Administration, ‘if a drug
product contains a drug substance that is chemically
identical and is delivered to the site of action at the same
rate and extent as another drug product, then it is equivalent and can be substituted for that drug product.’11
The aim of this study was to compare the pharmacokinetic proﬁles (PK) of PO and SC MTX in patients with
CD to determine the bioequivalence of these two routes
of administration.
Aliment Pharmacol Ther 2013; 37: 340-345
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MATERIALS AND METHODS
Patients
This single centre, nonrandomised, bioequivalence study
was carried out in London, Ontario, Canada. Recruitment
of patients took place from March 2009 to August 2011.
Eligible patients were at least 18 years of age with a history of CD who were starting on MTX therapy. Patients
receiving concurrent corticosteroids (n = 4) were eligible
for this study. Patients were excluded from the study for
the following reasons: use of MTX within 4 weeks of
study enrolment; pre-existing hepatic, pulmonary or renal
dysfunction; known pregnancy or ongoing breast-feeding;
history of cancer, erythrocyte macrocytosis or high alcohol consumption or MTX hypersensitivity. Written
informed consent was obtained from each patient. The
study protocol was approved by the University of Western
Ontario Health Sciences Research Ethics Board (15765).
Procedure
Patients were screened for eligibility 2 weeks prior to enrolment. Each patient underwent oesophagogastroduodenoscopy (EGD) to rule out upper gastrointestinal tract
CD involvement. All EGDs were normal. Body weight
and routine blood tests (blood count, biochemistries, liver
enzymes and creatinine) were measured for each patient.
All female patients were screened for pregnancy with a
urine pregnancy test. Demographic data, including CDrelated medications and disease activity (assessed using
the Crohn’s Disease Activity Index - CDAI) were collected for each patient. Each patient participated in two
separate Pk analyses (PO MTX and SC MTX). Each analysis occurred over the course of one study day separated
by one week’s duration as per the standard MTX dosing
interval. Patients were instructed to take nothing by
mouth the morning of their 2 study days. During each
study day, patients randomly received either a PO or a SC
25 mg dose of MTX. The dose of MTX was selected based
on the standard practice carried out at London Health
Sciences Centre (LHSC) for CD patients. Plasma collections at 10 prespeciﬁed time-points measured in hours (0,
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10) were obtained for MTX plasma
concentrations. MTX plasma concentrations were measured using a sensitive mass spectrometer. Patients were
monitored clinically for signs of MTX intolerance (hypersensitivity reaction, gastrointestinal upset).
Pharmacokinetic analysis
Pharmacokinetic (Pk) analysis was performed by the
noncompartmental method. PK parameters collected
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included the following: maximum plasma drug concentration (Cmax); time to the maximum plasma drug concentration (tmax); total drug exposure estimated by the
area of under the plasma concentration-time curve
(AUC); and the drug half-life (t1/2). The AUC of PO
and SC MTX for each patient was calculated using the
trapezoidal rule (numerical integration) and represents
the bioavailability of MTX administered either orally or
subcutaneously. The relative bioavailability (the fraction
of an administered dose of unchanged drug that reaches
the systemic circulation compared to the standard of
care) of oral MTX was calculated by determining the
ratio of AUCpo to AUCsc, assuming 100% bioavailability
of SC MTX.

Statistical analysis
Data are presented as the arithmetic mean. PK data for
PO and SC MTX were compared using a two-one-sidedtests procedure suggested by Schuirmann.12 Consider
lPO and lSC to be the population mean AUCs of PO
and SC respectively. The bioequivalence of PO and SC
can be tested using the following statistical hypotheses:
H0: lPO/lSC  h1 or lPO/lSC  h2 vs. HA: h1  lPO/

lSC < h2. The null hypothesis (H0) states that lPO and
lSC are not equivalent and the alternative hypothesis
(HA) states that lPO and lSC are equivalent. As recommended by the FDA (2001), the AUC was log-transformed using natural logarithms. The 90% CI for the
difference in the means of the log AUCs was calculated
and then antilog transformed to obtain the 90% CI of
the ratio of the mean AUCs between PO and SC.

RESULTS
Twelve CD patients were enrolled in this study. Their
baseline characteristics are highlighted in Table 1. One
patient was withdrawn from the protocol on the day of
the ﬁrst Pk analysis due to meeting one of the exclusion
criteria (high alcohol consumption) on re-assessment.
The PK analyses for the remaining 11 patients are summarised in Table S2 (published online).
The mean bioavailability of PO MTX and SC MTX
was
3375.0 ng/cc 9 h  1143
and
3985.4 ng/
cc 9 h  1556.7 respectively (Figure 1). The mean maximum concentrations were 955 ng/mL (PO) and
1163.6 ng/mL (SC). The times to maximum concentration were 1.4 h (PO) and 0.6 h (SC). The mean

Table 1 | Baseline characteristics

Patient Sex

Race

Disease
duration Intestinal
Concomitant
Age (years) involvement medications

1

M

Caucasian 53

5

Colon

2

M

Caucasian 29

3

Colon

3

F

Caucasian 52

17

Colon

4

M

Caucasian 43

4

Colon

5

F

Caucasian 34

0.75

Colon

6

M

Caucasian 28

7

7

F

Caucasian 56

40

8

M

Caucasian 29

14

Terminal
ileum
Ileum and
Colon
Ileum

9

F

Caucasian 56

9

Colon

10

F

Caucasian 56

7

11

F

Caucasian 47

21

Ileum and
colon
Ileum and
colon

CDAI Previous intestinal Laboratory
score resection
values

Asacol
1.2g BID
Nil

61

No resections

55

No resections

Pentasa
500mg BID
Budesonide
6mg daily
Nil

28

No resections

49

No resections

96

No resections

Prednisone
122
40mg daily
Prednisone
229
15mg daily
Remicaide
264
5mg/kg q8w
34
Budesonide
9mg daily
Nil

No resections
Small bowel
resections
Ileal resection
No resections

6

Ileal resection

24

Ileocecal
resection

Wbc 7.8, Hb 136, plts 299,
ALT 15, AST 16
Wbc 8.1, Hb 161, plts 213,
ALT 18, AST 22
Wbc 7.8, Hb 126, plts 390,
ALT 16, AST 30
Wbc 8.6, Hb 145, plts 336,
ALT 16, AST 16
Wbc 8.1, Hb 114, plts 245,
ALT 17, AST 12
Wbc 13.6, Hb 140, plts 291,
ALT 12, AST 17
Wbc 6.7, Hb 136, plts 236,
ALT 16, AST 20
Wbc 7.7, Hb 131, plts 276,
ALT 32, AST 24
Wbc 8.6, Hb 136, plts 273,
ALT 17, AST 16
Wbc 7.7, Hb 146, plts 320,
ALT 19, AST 19
Wbc 7.7, Hb 131, plts 276,
ALT 32, AST 24

CDAI, Crohn’s disease activity index; Wbc, white blood cells; Hb, haemoglobin; plts, platelets; ALT, alanine aminotransferase; AST,
aspartate aminotransferase.
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Figure 1 | The area under the curve (AUC) of PO (dark
bar) vs. SC (light bar) MTX in 11 patients with Crohn’s
disease. AUC represents the bioavailability expressed
as a rate of orally and subcutaneously administered
methotrexate.
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half-lives were 2.6 h (PO) and 2.9 h (SC). This is consistent with values quoted in the literature. The mean relative bioavailability (PO/SC) was 0.86  0.1. This
correlates with a mean relative PO bioavailability of 86%
in comparison to SC MTX with a range of 62–108%
(Figure 2). There were no adverse events.
According to the 80/125 rule proposed by FDA,13, 14
if the 90% conﬁdence interval (CI) of the ratio of the
averages of AUCs for two treatments (PO and SC)

Figure 2 | The relative bioavailability (the diamonded
grey line) of PO MTX vs. SC MTX in 11 patients with
Crohn’s disease. The Food and Drug Administration
(FDA) require a minimum relative bioavailability of
80% for two drugs (or routes of administration) to be
considered bioequivalent. The mean relative
bioavailability of the 11 study patients is represented by
the black line.
Aliment Pharmacol Ther 2013; 37: 340-345
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DISCUSSION
The mean relative bioavailability of PO MTX to SC
MTX is 0.86 in this study population. On average, there
is a 14% reduction in the bioavailability of PO compared
with SC MTX. This could be accounted for by presystemic metabolism (ﬁrst-pass effect) as well as possible
insufﬁcient absorption time, relating to the interpatient
variability in gut motility.15 Furthermore, competing
intraluminal reactions such as PO MTX hydrolysis by
gastric acids, digestive enzymes and luminal microﬂora
could contribute to the reduced bioavailability.15 The
90% conﬁdence interval for the mean AUC (PO/SC)
ratio (0.785, 0.929) falls just outside the range of the 80/
125 rule proposed by the FDA; therefore, the statistical
bioequivalence of these two routes cannot be concluded.13, 14 However, it should be noted that even
though there is a statistically signiﬁcant difference
between the bioavailability of PO and SC MTX, this may
not translate to a clinically signiﬁcant difference with
respect to overall MTX exposure.
A similar mean relative bioavailability of PO vs. SC
MTX was seen in a Pk study in non-CD patients.16
Jundt et al. examined the relative PO bioavailability of
MTX in comparison to parenterally administered MTX
in 12 RA patients. They found that the relative PO bioavailability of MTX was 0.85 when administered by tablet in comparison to parenteral administration.
Furthermore, there is evidence to support the use of oral
MTX in RA patients despite the fact that the PO vs. SC
bioavailabilities are not identical.17, 18
With respect to the CD patient population, earlier
studies examining the efﬁcacy of MTX as a treatment
for CD evaluated the parenteral administration of this
drug.2–4 It has been hypothesised that the reasoning
behind the exclusive evaluation of this route in the CD
population was due to the following: (i) limited oral
bioavailability relative to parenteral bioavailability; (ii)
greater interpatient variability in drug exposure with
oral administration.5 More recent studies by Kurnik
et al. and Stephens et al. fail to support these assumptions.
Stephens et al. conducted a PK analysis of PO and SC
MTX in a CD paediatric population.5 They found that
the relative bioavailability of PO vs. SC MTX was high
(0.84) and concluded that the dose rather than the route
343
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of administration was the most important factor inﬂuencing bioavailability. Similarly, they found that the interpatient variability is no more an issue in PO dosing
than in SC dosing.
A similar study in an adult CD population by Kurnik
et al. found a slightly lower mean relative PO bioavailability of 0.74.6 This may have been due to the lower
and variable doses of MTX used in that study compared
with the current study which used the same 25 mg dose
in all patients.
The current study is the ﬁrst of its kind to conduct
PK analyses in CD patients at the point of MTX initiation. Previously referenced studies have analysed the bioavailability of SC and PO MTX in patients who had
been on therapy for several weeks to months. Despite
their ﬁndings, Stephens et al. questioned whether or not
the high relative bioavailability of PO MTX was limited
to patients who were chronically on the medication. The
current study conﬁrms that the relative PO bioavailability of MTX at its initiation appears to be similar to that
seen in patients who have been on the drug for a prolonged period of time.
Therefore, the current study adds to this emerging
body of literature supporting the relative comparability
of PO and SC MTX in CD patients. Similarly to the
above mentioned studies, it highlights the lack of evidence to support the avoidance of PO MTX in CD
patients.
It should be noted that the majority of the patient
population in this study was in remission. This study
did not examine the effect of MTX on disease activity
or the effect of disease activity on MTX bioavailability.
Patients with small bowel and colonic resections were
included in this study (5/12). Four of the ﬁve patients
had limited ileal resections while one patient had several small bowel resections where the amount of bowel
removed could not be quantiﬁed. MTX is a highly speciﬁc substrate for the proton-coupled folate transporter,
that is maximally expressed in the duodenum and jejunum.19 Within our patient population, these areas
were not affected by disease or surgery. Thus methotrexate absorption may be different in CD patients with
an altered duodenum or jejunum by surgery or
inﬂammation.
Also, the patient population is this study were fasting
up until the time of PO MTX consumption and up to
two hours after the medication was ingested. Patients in
clinical practice will likely not be fasting and this could
possibly change the absorption of MTX if orally administered.
344

CONCLUSIONS
Further study to determine the cause of interpatient drug
bioavailability variability in CD, particularly in the setting of active disease or signiﬁcant upper GI involvement, is needed to more fully determine the overall
bioavailability and clinical dosing strategies. Nevertheless,
at least when CD is in remission, our data suggest that it
may be reasonable to offer PO MTX to patients requiring the drug, particularly in cases where compliance may
be compromised by a parenteral route of administration.
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